Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation
Orexigen Therapeutics, Inc. (OREXQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/13/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 13, 2017 OREXIGEN THERAPEUTICS, INC. Delaware 001-33415 65-1178822 3344 N. Torrey Pines Court, Suite 200 La Jolla, California 92037 Registrant's Telephone Number, Including Area Code: 875-8600 Not Applicable",
"Orexigen Therapeutics Announces Third Quarter 2017 Financial Results"
08/08/2017 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces Second Quarter 2017 Financial Results Contrave achieves all-time high for quarterly U.S. net sales, growing 69% year-over-year"
05/09/2017 8-K Form 8-K - Current report
03/28/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Quarterly results
Docs: "Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016"
11/12/2013 8-K Quarterly results
Docs: "Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013"
08/06/2013 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013"
05/08/2013 8-K Quarterly results
Docs: "Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013"
03/13/2013 8-K Quarterly results
Docs: "Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012"
08/07/2012 8-K Quarterly results
Docs: "Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012"
03/08/2012 8-K Quarterly results
Docs: "Orexigen ® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2011 Financial Results"
11/08/2011 8-K Form 8-K - Current report
08/08/2011 8-K Quarterly results
Docs: "Orexigen ® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results"
05/09/2011 8-K Quarterly results
Docs: "Orexigen ® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results"
03/10/2011 8-K Form 8-K - Current report
11/03/2010 8-K Quarterly results
Docs: "Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results"
08/05/2010 8-K Form 8-K - Current report
05/10/2010 8-K Quarterly results
Docs: "OREXIGEN Therapeutics Reports First Quarter 2010 Financial and Operational Results"
03/09/2010 8-K Quarterly results
Docs: "OREXIGEN Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results"
08/06/2009 8-K Quarterly results
Docs: "Orexigen® Therapeutics Announces Second Quarter 2009 Financial Results"
05/07/2009 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces First Quarter 2009 Financial Results"
03/12/2009 8-K Quarterly results
Docs: "OREXIGEN Therapeutics Announces Fourth Quarter and Year Ended December 31, 2008 Financial Results"
11/06/2008 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces Third Quarter 2008 Financial Results"
08/07/2008 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces Second Quarter 2008 Financial Results"
05/08/2008 8-K Quarterly results
Docs: "Orexigen Therapeutics Announces First Quarter 2008 Financial Results"
03/13/2008 8-K Quarterly results
Docs: "OREXIGEN Therapeutics Announces Fourth Quarter and Year Ended December 31, 2007 Financial Results"
11/08/2007 8-K Quarterly results
Docs: "Second Amendment to Credit and Security Agreement by and between the Registrant and Merrill Lynch Capital",
"OREXIGEN™ Therapeutics Announces Third Quarter 2007 Financial Results"
08/09/2007 8-K Quarterly results
Docs: "OREXIGEN™ Therapeutics Announces Second Quarter 2007 Financial Results"
05/30/2007 8-K Quarterly results
Docs: "OREXIGEN™ Therapeutics Announces First Quarter 2007 Financial Results San Diego, CA, May 25, 2007 — Orexigen™ Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders, with an initial focus on obesity, today announced unaudited financial results for the first quarter ended March 31, 2007. For the three months ended March 31 2007, Orexigen reported a net loss of $12.2 million, or $5.26 per share attributable to common shareholders, as compared to a net loss of $5.2 million, or $2.49 per share, for the same period in 2006. As of March 31, 2007, Orexigen held cash and cash equivalents of $32.3 million. In the second quarter of 2007, Orexigen completed its initial public offering which generated net proceeds of $88.0 million from the sale of..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy